Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects
Identifieur interne : 001A20 ( Main/Exploration ); précédent : 001A19; suivant : 001A21Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects
Auteurs :Source :
- Movement Disorders [ 0885-3185 ] ; 2010-09-15.
English descriptors
- KwdEn :
- Analysis of Variance, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Huntington Disease (drug therapy), Huntington's disease, Male, Treatment Outcome, Ubiquinone (administration & dosage), Ubiquinone (adverse effects), Ubiquinone (analogs & derivatives), Ubiquinone (therapeutic use), coenzyme Q10, safety, tolerability.
- MESH :
- chemical , administration & dosage : Ubiquinone.
- chemical , adverse effects : Ubiquinone.
- chemical , analogs & derivatives : Ubiquinone.
- drug therapy : Huntington Disease.
- chemical , therapeutic use : Ubiquinone.
- Analysis of Variance, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Male, Treatment Outcome.
Abstract
Coenzyme Q10 (CoQ10), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ10 dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg/day of CoQ10 in HD and healthy subjects. Twenty‐eight subjects (20 HD, 8 healthy) enrolled in a 20‐week open‐label trial. Subjects started on 1,200 mg/day of CoQ10, increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg/day. Monthly evaluations included review of adverse events and CoQ10 blood levels. Twenty‐three subjects (82%) achieved the target dosage of 3,600 mg/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ10. The most common adverse events seen were GI symptoms. Mean (± SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 ± 1.27 μg/mL (baseline, n = 28), 5.59 ± 2.24 μg/mL (1,200 mg/day, week 4, n = 26), 6.38 ± 3.25 μg/mL (2,400 mg/day, week 8, n = 25), 7.49 ± 4.09 μg/mL (3,600 mg/day, week 12, n = 23), and 6.78 ± 3.36μg/mL (3,600 mg/day, week 20, n = 20). CoQ10 was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg/day are planned. © 2010 Movement Disorder Society.
Url:
DOI: 10.1002/mds.22408
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001878
- to stream Istex, to step Curation: 001878
- to stream Istex, to step Checkpoint: 000699
- to stream PubMed, to step Corpus: 001662
- to stream PubMed, to step Curation: 001662
- to stream PubMed, to step Checkpoint: 001626
- to stream Ncbi, to step Merge: 002D55
- to stream Ncbi, to step Curation: 002D55
- to stream Ncbi, to step Checkpoint: 002D55
- to stream Main, to step Merge: 001E56
- to stream Main, to step Curation: 001A20
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects</title>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:690B9955BD2FF426EEB9E15135C42B374D561040</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22408</idno>
<idno type="url">https://api.istex.fr/document/690B9955BD2FF426EEB9E15135C42B374D561040/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001878</idno>
<idno type="wicri:Area/Istex/Curation">001878</idno>
<idno type="wicri:Area/Istex/Checkpoint">000699</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:20669312</idno>
<idno type="wicri:Area/PubMed/Corpus">001662</idno>
<idno type="wicri:Area/PubMed/Curation">001662</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001626</idno>
<idno type="wicri:Area/Ncbi/Merge">002D55</idno>
<idno type="wicri:Area/Ncbi/Curation">002D55</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002D55</idno>
<idno type="wicri:Area/Main/Merge">001E56</idno>
<idno type="wicri:Area/Main/Curation">001A20</idno>
<idno type="wicri:Area/Main/Exploration">001A20</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects</title>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-09-15">2010-09-15</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1924">1924</biblScope>
<biblScope unit="page" to="1928">1928</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">690B9955BD2FF426EEB9E15135C42B374D561040</idno>
<idno type="DOI">10.1002/mds.22408</idno>
<idno type="ArticleID">MDS22408</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Huntington Disease (drug therapy)</term>
<term>Huntington's disease</term>
<term>Male</term>
<term>Treatment Outcome</term>
<term>Ubiquinone (administration & dosage)</term>
<term>Ubiquinone (adverse effects)</term>
<term>Ubiquinone (analogs & derivatives)</term>
<term>Ubiquinone (therapeutic use)</term>
<term>coenzyme Q10</term>
<term>safety</term>
<term>tolerability</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Huntington Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Ubiquinone</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Administration Schedule</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Coenzyme Q10 (CoQ10), a potential neuroprotective compound, was previously investigated at a dosage of 600 mg/day in Huntington's disease (HD) patients and demonstrated a trend toward slowing disease progression. Higher CoQ10 dosages may prove beneficial. We investigated the tolerability and blood levels associated with 1,200, 2,400, and 3,600 mg/day of CoQ10 in HD and healthy subjects. Twenty‐eight subjects (20 HD, 8 healthy) enrolled in a 20‐week open‐label trial. Subjects started on 1,200 mg/day of CoQ10, increasing every 4 weeks by 1,200 mg to a maximum dosage of 3,600 mg/day. Monthly evaluations included review of adverse events and CoQ10 blood levels. Twenty‐three subjects (82%) achieved the target dosage of 3,600 mg/day. Six subjects (2 healthy, 4 HD) withdrew prematurely (gastrointestinal (GI) symptoms in 3, worsening HD in 2, and 1 because of a fall). All three serious adverse events occurred in a single subject, and were deemed unrelated to CoQ10. The most common adverse events seen were GI symptoms. Mean (± SD) CoQ10 blood levels achieved over the course of the trial were as follows: 1.26 ± 1.27 μg/mL (baseline, n = 28), 5.59 ± 2.24 μg/mL (1,200 mg/day, week 4, n = 26), 6.38 ± 3.25 μg/mL (2,400 mg/day, week 8, n = 25), 7.49 ± 4.09 μg/mL (3,600 mg/day, week 12, n = 23), and 6.78 ± 3.36μg/mL (3,600 mg/day, week 20, n = 20). CoQ10 was well tolerated with over 80% of subjects achieving the target dosage. Dosages of 2,400 mg/day may provide the best balance between tolerability and blood level achieved. Further studies examining the efficacy of 2,400 mg/day are planned. © 2010 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list></list>
<tree></tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:690B9955BD2FF426EEB9E15135C42B374D561040 |texte= Safety and tolerability of high‐dosage coenzyme Q10 in Huntington's disease and healthy subjects }}
This area was generated with Dilib version V0.6.23. |